,trastuzumab deruxtecan
astrazeneca,daiichi sankyo
['breast', 'destiny-breast04']
her2 targeted therapy has not been successful in treating cancer that is her2-low, until now. msk s dr. modi shares the encouraging results from the destiny-breast04, a randomized, phase 3 study at #asco22. 
The official account of Memorial Sloan Kettering Cancer Center, the Sloan Kettering Institute, and Louis V. Gerstner, Jr. Graduate School of Biomedical Sciences